Urocortin: a protective peptide that targets both the myocardium and vasculature

被引:28
作者
Davidson, Sean M. [1 ]
Yellon, Derek M. [1 ]
机构
[1] Univ Coll London Hosp & Med Sch, Hatter Cardiovasc Inst, London WC1E 6HX, England
基金
英国医学研究理事会;
关键词
urocortin; heart; heart failure; cardiomyocytes; endothelial cells; CORTICOTROPIN-RELEASING-FACTOR; EXPERIMENTAL HEART-FAILURE; ISOLATED RAT-HEART; ANGIOTENSIN-CONVERTING ENZYME; ISCHEMIA-REPERFUSION INJURY; STRESSCOPIN-RELATED PEPTIDE; NITRIC-OXIDE; CARDIAC MYOCYTES; CONSCIOUS RATS; FACTOR CRF;
D O I
10.1016/S1734-1140(09)70019-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The urocortins are a family of endogenously produced peptide hormones that show great promise as potential drugs for the treatment of heart disease. They can increase contractility and cardiac output without causing changes in mean arterial blood pressure. As expected, the receptor for these peptides is present in cardiomyocytes, and they can bind and protect these cells from simulated ischemia and reperfusion in vitro. The receptor is present, however, in much higher density in the endothelial cells that form a continuous lining of the coronary vasculature. Functionally, the urocortin peptides have been shown to have potent local vasodilatory effects, and may affect other aspects of vascular function. In this review, we will attempt to distinguish the "cardio" from the "vascular" effects of urocortin and its homologues, including the archetypal family member, corticotrophin releasing hormone.
引用
收藏
页码:172 / 182
页数:11
相关论文
共 79 条
[1]   Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats [J].
Abdelrahman, AM ;
Lim, SL ;
Pang, CCY .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 510 (1-2) :107-111
[2]   Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response [J].
Baigent, SM .
PEPTIDES, 2001, 22 (05) :809-820
[3]   The cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure [J].
Bale, TL ;
Hoshijima, M ;
Gu, Y ;
Dalton, N ;
Anderson, KR ;
Lee, KF ;
Rivier, J ;
Chien, KR ;
Vale, WW ;
Peterson, KL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (10) :3697-3702
[4]   Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress [J].
Bale, TL ;
Contarino, AB ;
Smith, GW ;
Chan, R ;
Gold, LH ;
Sawchenko, PE ;
Koob, GF ;
Vale, WW ;
Lee, KF .
NATURE GENETICS, 2000, 24 (04) :410-414
[5]   Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization [J].
Bale, TL ;
Giordano, FJ ;
Hickey, RP ;
Huang, Y ;
Nath, AK ;
Peterson, KL ;
Vale, WW ;
Lee, KF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) :7734-7739
[6]   Studies of the role of endothelium-dependent nitric oxide release in the sustained vasodilator effects of corticotrophin releasing factor and sauvagine [J].
Barker, DM ;
Corder, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) :317-325
[7]  
Bauersachs J, 2008, PHARMACOL REP, V60, P119
[8]  
Bernacki J, 2008, PHARMACOL REP, V60, P600
[9]   Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway [J].
Brar, BK ;
Jonassen, AK ;
Stephanou, A ;
Santilli, G ;
Railson, J ;
Knight, RA ;
Yellon, DM ;
Latchman, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8508-8514
[10]   Urocortin-II and Urocortin-III are cardioprotective against ischemia reperfusion injury: An essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart [J].
Brar, BK ;
Jonassen, AK ;
Egorina, EM ;
Chen, A ;
Negro, A ;
Perrin, MH ;
Mjos, OD ;
Latchman, DS ;
Lee, KF ;
Vale, W .
ENDOCRINOLOGY, 2004, 145 (01) :24-35